Chondroitin Sulfate

In patients with knee osteoarthritis, oral chondroitin sulfate significantly reduced cartilage volume loss at 6 months and decreased subchondral bone marrow lesion progression at 12 and 24 months compared with placebo, while safety was comparable to placebo.

This meta-analysis of clinical trials found that chondroitin sulfate produced small but statistically significant benefits on pain, function, and minimum joint space narrowing in osteoarthritis, particularly at doses around 1200 mg per day.

This critical review concluded that properly standardized, pharmacologic‑grade chondroitin sulfate may provide clinically meaningful improvements in pain and function and modest structural benefits in osteoarthritis, while emphasizing that high‑quality, large trials are still needed to confirm efficacy.

This Cochrane review found that chondroitin sulfate was better than placebo in improving pain and quality of life in osteoarthritis, while also highlighting substantial heterogeneity and variable study quality across trials.

This evidence review reported small to medium improvements in pain and physical function in osteoarthritis with chondroitin sulfate, noted that manufacturer‑funded trials tended to show more positive results, and concluded that the supplement appears very safe but its effectiveness is not firmly established.

This Cochrane review found that chondroitin sulfate was better than placebo in improving pain and quality of life in osteoarthritis, while also highlighting substantial heterogeneity and variable study quality across trials.

This critical review concluded that properly standardized, pharmacologic‑grade chondroitin sulfate may provide clinically meaningful improvements in pain and function and modest structural benefits in osteoarthritis, while emphasizing that high‑quality, large trials are still needed to confirm efficacy.

This meta-analysis of clinical trials found that chondroitin sulfate produced small but statistically significant benefits on pain, function, and minimum joint space narrowing in osteoarthritis, particularly at doses around 1200 mg per day.

In a six‑year double‑blind, placebo‑controlled trial in adults with coronary artery disease, long‑term chondroitin sulfate use was associated with a markedly lower rate of fatal and non‑fatal myocardial infarction compared with placebo.

This review summarized cohort data showing that regular chondroitin sulfate use in generally healthy adults was associated with lower all‑cause and cardiovascular mortality and discussed mechanistic links to extracellular matrix maintenance and reduced chronic inflammation.

In a six‑year double‑blind, placebo‑controlled trial in adults with coronary artery disease, long‑term chondroitin sulfate use was associated with a markedly lower rate of fatal and non‑fatal myocardial infarction compared with placebo.

This review summarized cohort data showing that regular chondroitin sulfate use in generally healthy adults was associated with lower all‑cause and cardiovascular mortality and discussed mechanistic links to extracellular matrix maintenance and reduced chronic inflammation.

This review summarized cohort data showing that regular chondroitin sulfate use in generally healthy adults was associated with lower all‑cause and cardiovascular mortality and discussed mechanistic links to extracellular matrix maintenance and reduced chronic inflammation.

This critical review concluded that properly standardized, pharmacologic‑grade chondroitin sulfate may provide clinically meaningful improvements in pain and function and modest structural benefits in osteoarthritis, while emphasizing that high‑quality, large trials are still needed to confirm efficacy.

This critical review concluded that properly standardized, pharmacologic‑grade chondroitin sulfate may provide clinically meaningful improvements in pain and function and modest structural benefits in osteoarthritis, while emphasizing that high‑quality, large trials are still needed to confirm efficacy.

In patients with knee osteoarthritis, oral chondroitin sulfate significantly reduced cartilage volume loss at 6 months and decreased subchondral bone marrow lesion progression at 12 and 24 months compared with placebo, while safety was comparable to placebo.

This meta-analysis of clinical trials found that chondroitin sulfate produced small but statistically significant benefits on pain, function, and minimum joint space narrowing in osteoarthritis, particularly at doses around 1200 mg per day.

This critical review concluded that properly standardized, pharmacologic‑grade chondroitin sulfate may provide clinically meaningful improvements in pain and function and modest structural benefits in osteoarthritis, while emphasizing that high‑quality, large trials are still needed to confirm efficacy.

This meta-analysis of clinical trials found that chondroitin sulfate produced small but statistically significant benefits on pain, function, and minimum joint space narrowing in osteoarthritis, particularly at doses around 1200 mg per day.

This critical review concluded that properly standardized, pharmacologic‑grade chondroitin sulfate may provide clinically meaningful improvements in pain and function and modest structural benefits in osteoarthritis, while emphasizing that high‑quality, large trials are still needed to confirm efficacy.

This meta-analysis of clinical trials found that chondroitin sulfate produced small but statistically significant benefits on pain, function, and minimum joint space narrowing in osteoarthritis, particularly at doses around 1200 mg per day.

This critical review concluded that properly standardized, pharmacologic‑grade chondroitin sulfate may provide clinically meaningful improvements in pain and function and modest structural benefits in osteoarthritis, while emphasizing that high‑quality, large trials are still needed to confirm efficacy.

This meta-analysis of clinical trials found that chondroitin sulfate produced small but statistically significant benefits on pain, function, and minimum joint space narrowing in osteoarthritis, particularly at doses around 1200 mg per day.

This critical review concluded that properly standardized, pharmacologic‑grade chondroitin sulfate may provide clinically meaningful improvements in pain and function and modest structural benefits in osteoarthritis, while emphasizing that high‑quality, large trials are still needed to confirm efficacy.